Pharmacophore modeling and parallel screening for PPAR ligands
暂无分享,去创建一个
Thierry Langer | Daniela Schuster | Johannes Kirchmair | Christian Laggner | Patrick Markt | C. Laggner | T. Langer | D. Schuster | P. Markt | J. Kirchmair | Christian Laggner
[1] Jianhua Shen,et al. Agonist–PPARγ interactions: Molecular modeling study with docking approach , 2003 .
[2] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[3] J. Berger,et al. (2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents. , 2005, Bioorganic & medicinal chemistry letters.
[4] J. Fleckner,et al. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. , 2003, Journal of medicinal chemistry.
[5] J. Berger,et al. Design and synthesis of potent and subtype-selective PPARα agonists , 2006 .
[6] N. Roglans,et al. Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. , 1999, Biochemical and biophysical research communications.
[7] Thierry Langer,et al. Influenza Virus Neuraminidase Inhibitors: Generation and Comparison of Structure-Based and Common Feature Pharmacophore Hypotheses and Their Application in Virtual Screening , 2004, J. Chem. Inf. Model..
[8] Theodora M. Steindl,et al. Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein. , 2005, Journal of medicinal chemistry.
[9] J. Lehmann,et al. The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .
[10] Thierry Langer,et al. Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) Inhibitors , 2006, J. Chem. Inf. Model..
[11] A. Dixit,et al. Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-L-tyrosines as PPAR gamma agonists. , 2004, Bioorganic & medicinal chemistry.
[12] J. Lehmann,et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.
[13] Ingrid Pettersson,et al. Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity , 2002 .
[14] T. Willson,et al. Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. , 2001, Bioorganic & medicinal chemistry letters.
[15] W. Hsueh,et al. Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[16] J. Lehmann,et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.
[17] T. Burris,et al. Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. , 2004, Journal of medicinal chemistry.
[18] L. Jendeberg,et al. A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects* , 2004, Journal of Biological Chemistry.
[19] K. Umesono,et al. Alteration of a Single Amino Acid in Peroxisome Proliferator-Activated Receptor-α (PPARα) Generates a PPARδ Phenotype , 2000 .
[20] M. Yachi,et al. Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship. , 2000, Bioorganic & medicinal chemistry letters.
[21] David J. Diller,et al. Use of Catalyst Pharmacophore Models for Screening of Large Combinatorial Libraries , 2002, J. Chem. Inf. Comput. Sci..
[22] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[23] Thierry Langer,et al. Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..
[24] David Q. Liu,et al. IN VITRO METABOLISM OF MK-0767 [(±)-5-[(2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL]-2-METHOXY-N-[[(4-TRIFLUOROMETHYL) PHENYL]METHYL]BENZAMIDE], A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α/γ AGONIST. I. ROLE OF CYTOCHROME P450, METHYLTRANSFERASES, FLAVIN MONOOXYGENASES, AND ESTERASES , 2004, Drug Metabolism And Disposition.
[25] Thierry Langer,et al. Development and validation of an in silico P450 profiler based on pharmacophore models. , 2006, Current drug discovery technologies.
[26] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[27] A. Tenenbaum,et al. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons , 2005, Cardiovascular Diabetology.
[28] Leming Shi,et al. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators. , 2004, Bioorganic & medicinal chemistry letters.
[29] S. Miyamoto,et al. Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. , 2001, Journal of molecular graphics & modelling.
[30] Armin Ruf,et al. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro , 2006 .
[31] J. Berger,et al. Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity. , 2005, Journal of medicinal chemistry.
[32] D. Diller,et al. Kinases, homology models, and high throughput docking. , 2003, Journal of medicinal chemistry.
[33] Ping-Chiang Lyu,et al. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. , 2006, Journal of medicinal chemistry.
[34] W. Miller,et al. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. , 2004, Journal of molecular endocrinology.
[35] L. Moore,et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Lehmann,et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[37] Terry K. Smith,et al. Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. , 2006, Journal of molecular biology.
[38] R. Epple,et al. 1,3,5-Trisubstituted aryls as highly selective PPARδ agonists , 2006 .
[39] P. Whittaker,et al. PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κB‐independent effect , 2003 .
[40] Henrik Boström,et al. Improving structure-based virtual screening by multivariate analysis of scoring data. , 2003, Journal of medicinal chemistry.